Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847150 | 0.88 | DRD2 (0.36) | DRD2DRD4DRD3ALOX15CREBBP | |
| SCHEMBL5847788 | 0.87 | CRHR1 (0.36) | DRD2DRD4DRD3 | |
| SCHEMBL25045802 | 0.72 | DRD2 (0.40) | DRD2DRD4DRD3NPC1RAB9A | |
| SCHEMBL25044269 | 0.71 | DRD2 (0.41) | DRD2DRD4DRD3 | |
| SCHEMBL5847103 | 0.70 | DRD3 (0.43) | DRD2DRD4DRD3ALDH1A1NPC1 | |
| SCHEMBL5847248 | 0.70 | CRHR1 (0.39) | ALDH1A1CYP3A4NPC1MAPTHPGD | |
| SCHEMBL5848725 | 0.69 | CRHR1 (0.44) | — | |
| SCHEMBL5848590 | 0.66 | CRHR1 (0.41) | — | |
| SCHEMBL5848759 | 0.65 | CRHR1 (0.48) | — | |
| SCHEMBL5848414 | 0.62 | CRHR1 (0.41) | ALOX15CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151109-B2 | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1485384-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | Pharmacia & Upjohn Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003078435-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | CRHR1, HTR5A, CRH | DRD2 145/4885DRD4 184/4885DRD3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.